阿立哌唑

**阿立哌唑**
系统（IUPAC）命名名称
	7-[4-[4-(2,3-二氯苯基)-1-哌嗪基]丁氧基]-3,4-二氢-2(1H)-喹啉酮 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydroquinolin-2(1H)-one
临床数据
商品名	Abilify
Drugs.com	Monograph
MedlinePlus	a603012
医疗法规	EU EMA: Abilify; US FDA: Aripiprazole;
妊娠分级	C (USA);
给药途径	口服 (via tablets, orodispersable tablets, and oral solution)、肌肉注射
合法狀態
合法状态	处方药（℞-only）;
药代动力学数据
生物利用度	87%
蛋白结合度	>99%
代谢	肝
生物半衰期	75小时 (active metabolite : 94小时)
排泄	腎臟及糞便
识别
CAS注册号	129722-12-9
ATC代码	N05AX12
PubChem	CID 60795
IUPHAR/BPS	34
DrugBank	DB01238
ChemSpider	54790
UNII	82VFR53I78
KEGG	D01164
ChEBI	CHEBI:31236
ChEMBL	CHEMBL1112
化学
化学式	C23H27Cl2N3O2
摩尔质量	448.385
	SMILES Clc4cccc(N3CCN(CCCCOc2ccc1c(NC(=O)CC1)c2)CC3)c4Cl;
	InChI InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29) ; Key:CEUORZQYGODEFX-UHFFFAOYSA-N ;

阿立哌唑（英語：）是一種非典型的抗精神病藥，常見商品名安立復（Abilify），化學式C₂₃H₂₇Cl₂N₃O₂。它主要用於治療精神分裂症和躁鬱症。其他用途包括作為重症憂鬱症、抽動綜合症與自閉症相關的附加治療藥物。使用方法有服用口服或肌肉注射[1]。

常見的副作用包括嘔吐、便秘、嗜睡、頭暈、反眼、體重增加和運動障礙等。嚴重的副作用可能包括遲發性運動不能、抗精神藥物惡性症候群和過敏反應。由於死亡風險增加，不建議患有阿茲海默症的老年人使用。有研究顯示在懷孕期間使用阿立哌唑可能會對嬰兒造成傷害，故建議有進行哺乳行為的婦女不要使用[2]。本藥品確切的作用方式尚未明朗，可能與多巴胺和5-羥色胺有關。

阿立哌唑是由日本大塚製藥公司的科學家於1988年研發出來的[3]。阿立哌唑於2002年在美國核准上市。截至2019年，在英國本品每月正常劑量約為2.75英鎊[4]。

參考文獻

"Aripiprazole, ARIPiprazole Lauroxil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 February 2019.
"Prescribing medicines in pregnancy database" 页面存档备份，存于. Australian Government. 3 March 2014. Retrieved 22 April 2014.
"Aripiprazole". AdisInsight. Retrieved 4 June 2017.
Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 392. ISBN 9780857113382.

外部連結

"Aripiprazole, ARIPiprazole Lauroxil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 February 2019.
"Aripiprazole, ARIPiprazole Lauroxil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 February 2019. 、"Prescribing medicines in pregnancy database" 页面存档备份，存于互联网档案馆. Australian Government. 3 March 2014. Retrieved 22 April 2014.
"Aripiprazole". AdisInsight. Retrieved 4 June 2017. Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 392. ISBN 9780857113382.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Aripiprazole, ARIPiprazole Lauroxil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 February 2019.

[2] "Aripiprazole, ARIPiprazole Lauroxil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 26 February 2019. 、"Prescribing medicines in pregnancy database" 页面存档备份，存于互联网档案馆. Australian Government. 3 March 2014. Retrieved 22 April 2014.

[3] "Aripiprazole". AdisInsight. Retrieved 4 June 2017. Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.

[4] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 392. ISBN 9780857113382.